• Arthritis/rheumatic disorders

Zilretta Generic Name & Formulations

General Description

Triamcinolone acetonide ext-rel 32mg; per vial; susp for intra-articular inj after dilution.

Pharmacological Class


How Supplied

Single-dose kit—1 (vial + diluent + adapter)

Generic Availability


Zilretta Indications


Osteoarthritis pain of the knee.

Limitations of Use

The efficacy and safety of repeat administration have not been demonstrated.

Zilretta Dosage and Administration


Give 32mg (5mL) as a single intra-articular inj.


Not established.

Zilretta Contraindications

Not Applicable

Zilretta Boxed Warnings

Not Applicable

Zilretta Warnings/Precautions


Not interchangeable with other injectable triamcinolone acetonide formulations. For intra-articular injection only. Not for epidural or intrathecal use; serious neurologic events may occur. Not suitable for use in small joints (eg, hand). Previously infected or unstable joints: not recommended. Increased risk of infections (viral, bacterial, fungal, protozoan, or helminthic). May mask signs of current infection. Avoid exposure to chickenpox or measles if unvaccinated. HPA axis suppression. Adrenal insufficiency. Supplement with additional corticosteroids in physiologic stress (eg, trauma, surgery, illness). Hypo- or hyperthyroidism. Patients with CHF, hypertension, renal insufficiency: monitor; dietary salt restriction and K+ supplementation may be necessary. Elevated intraocular pressure (monitor). Increased GI perforation risk in those with active or latent peptic ulcers, diverticulosis, diverticulitis, ulcerative colitis, intestinal anastomoses; avoid. Increased osteoporosis risk (eg, postmenopausal women). Emotional instability or psychiatric disorder; monitor for new or worsening behavior or mood disturbances. Pregnancy. Nursing mothers.

Zilretta Pharmacokinetics

See Literature

Zilretta Interactions


Potentiated by CYP3A4 inhibitors (eg, ketoconazole), cyclosporine, estrogens, macrolide antibiotics. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine. May potentiate cyclosporine (seizure risk). May antagonize oral anticoagulants (monitor), isoniazid. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin or other NSAIDs. Caution with aspirin in hypoprothrombinemia. Monitor for hypokalemia with K+-depleting drugs (eg, amphotericin B, diuretics). Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. May suppress reactions to skin tests. Defer routine vaccine or toxoid administration until corticosteroid is discontinued.

Zilretta Adverse Reactions

Adverse Reactions

Sinusitis, cough, contusions; joint tissue damage, infection, cardiovascular effects, renal effects, GI perforation, endocrine function or bone density alterations, behavioral and mood disturbances; rare: anaphylaxis.

Zilretta Clinical Trials

See Literature

Zilretta Note

Not Applicable

Zilretta Patient Counseling

See Literature